David E. Ehmann

3.0k citations

29 papers · 2.2k indexed · h-index 22

Impact in

Molecular Medicine top 0.2%
- Antibiotic Resistance in Bacteria
Applied Microbiology and Biotechnology top 1%
- Antibiotic Use and Resistance

Papers in ⓘ

Molecular Medicine 12
- Antibiotic Resistance in Bacteria 12
Pharmacology 16
- Antibiotics Pharmacokinetics and Efficacy 9
- Microbial Natural Products and Biosynthesis 7

Co-authors: Christopher T. Walsh (6 shared papers)Stewart L. Fisher (6 shared papers)Rong-Fang Gu (3 shared papers)Haris Jahić (5 shared papers)Grant K. Walkup (4 shared papers)Philip L. Ross (3 shared papers)Jun Hu (2 shared papers)Sushmita D. Lahiri (3 shared papers)
Journals: Antimicrobial Agents and Chemotherapy (5 papers)Journal of Biological Chemistry (2 papers)ChemBioChem (2 papers)Journal of Medicinal Chemistry (2 papers)Biochemistry (2 papers)
Partner nations: United States United Kingdom Canada

In The Last Decade

David E. Ehmann

29 papers receiving 2.1k citations

Peers

Countries citing papers authored by David E. Ehmann

Since Specialization

Citations

This map shows the geographic impact of David E. Ehmann's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by David E. Ehmann with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites David E. Ehmann more than expected).

Fields of papers citing papers by David E. Ehmann

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by David E. Ehmann. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by David E. Ehmann. The network helps show where David E. Ehmann may publish in the future.

Co-authors

The 25 scholars most cited alongside David E. Ehmann, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with David E. Ehmann Line = papers co-authored together David E. Ehmann links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Showing the 20 most-cited of 29 papers — load more, or switch the sort, to bring in the rest.

#	Work
1	Avibactam is a covalent, reversible, non–β-lactam β-lactamase inhibitor Proceedings of the National Academy of Sciences ·David E. Ehmann, Haris Jahić, Philip L. Ross, Rong-Fang Gu, Jun Hu, Günther Kern, Grant K. Walkup, Stewart L. Fisher	2012	410
2	Kinetics of Avibactam Inhibition against Class A, C, and D β-Lactamases Journal of Biological Chemistry ·David E. Ehmann, Haris Jahić, Philip L. Ross, Rong-Fang Gu, Jun Hu, Thomas F. Durand-Réville, Sushmita D. Lahiri, Jason Thresher, Stephania Livchak, Ning Gao, Tiffany Palmer, Grant K. Walkup, Stewart L. Fisher	2013	301
3	Molecular Mechanisms of Sulbactam Antibacterial Activity and Resistance Determinants in Acinetobacter baumannii Antimicrobial Agents and Chemotherapy ·William F. Penwell, Adam B. Shapiro, R.A. Giacobbe, Rong-Fang Gu, Ning Gao, Jason Thresher, Robert E. McLaughlin, Michael D. Huband, Boudewijn L DeJonge, David E. Ehmann, Alita A. Miller	2015	183
4	Lysine Biosynthesis in Saccharomyces cerevisiae: Mechanism of α-Aminoadipate Reductase (Lys2) Involves Posttranslational Phosphopantetheinylation by Lys5 Biochemistry ·David E. Ehmann, Amy M. Gehring, Christopher T. Walsh	1999	140
5	Translating slow-binding inhibition kinetics into cellular and in vivo effects Nature Chemical Biology ·Grant K. Walkup, Zhiping You, Philip L. Ross, Eleanor K. H. Allen, Fereidoon Daryaee, Michael Hale, John C. O’Donnell, David E. Ehmann, Virna Schuck, Ed T. Buurman, Allison L. Choy, Laurel Hajec, Kerry E. Murphy-Benenato, Valerie Marone, Sara A. Patey, Lena A Grosser, Michele Johnstone, Stephen G. Walker, Peter J. Tonge, Stewart L. Fisher	2015	116
6	Aminoacyl-SNACs as small-molecule substrates for the condensation domains of nonribosomal peptide synthetases Chemistry & Biology ·David E. Ehmann, John W. Trauger, Torsten Stachelhaus, Christopher T. Walsh	2000	97
7	The EntF and EntE adenylation domains of Escherichia coli enterobactin synthetase: Sequestration and selectivity in acyl-AMP transfers to thiolation domain cosubstrates Proceedings of the National Academy of Sciences ·David E. Ehmann, Cathryn A. Shaw-Reid, Heather C. Losey, Christopher T. Walsh	2000	92
8	Molecular Basis of Selective Inhibition and Slow Reversibility of Avibactam against Class D Carbapenemases: A Structure-Guided Study of OXA-24 and OXA-48 ACS Chemical Biology ·Sushmita D. Lahiri, Stefano Mangani, Haris Jahić, Manuela Benvenuti, Thomas F. Durand-Réville, Filomena De Luca, David E. Ehmann, Gian María Rossolini, Richard A. Alm, Jean‐Denis Docquier	2014	90
9	Novel N-Linked Aminopiperidine Inhibitors of Bacterial Topoisomerase Type II: Broad-Spectrum Antibacterial Agents with Reduced hERG Activity Journal of Medicinal Chemistry ·Folkert Reck, Richard A. Alm, Patrick Brassil, Joseph P. Newman, Boudewijn L DeJonge, Charles J. Eyermann, Gloria A. Breault, John Breen, Janelle Comita-Prevoir, M Cronin, Hajnalka E. Davis, David E. Ehmann, Vincent Galullo, Bolin Geng, Tyler Grebe, Marshall Morningstar, P Craig Walker, Barry R. Hayter, Stewart L. Fisher	2011	86
10	Untargeted Metabolomics To Ascertain Antibiotic Modes of Action Antimicrobial Agents and Chemotherapy ·Isabel M. Vincent, David E. Ehmann, Scott D. Mills, Manos Perros, Michael P. Barrett	2016	70
11	Pharmacodynamic Profiling of a Siderophore-Conjugated Monocarbam in Pseudomonas aeruginosa: Assessing the Risk for Resistance and Attenuated Efficacy Antimicrobial Agents and Chemotherapy ·Aryun Kim, Amy Kutschke, David E. Ehmann, Sara A. Patey, Jared L. Crandon, Elise Gorseth, Alita A. Miller, Robert E. McLaughlin, Christina M. Blinn, April Chen, Asha S. Nayar, Brian Dangel, Andy S. Tsai, Michael Rooney, Kerry E. Murphy-Benenato, Ann E. Eakin, David P. Nicolau	2015	66
12	Novel N-Linked Aminopiperidine Inhibitors of Bacterial Topoisomerase Type II with Reduced pK_a: Antibacterial Agents with an Improved Safety Profile Journal of Medicinal Chemistry ·Folkert Reck, Richard A. Alm, Patrick Brassil, Joseph Newman, Paul J. Ciaccio, John McNulty, Herbert Barthlow, Kosalaram Goteti, John Breen, Janelle Comita-Prevoir, M Cronin, David E. Ehmann, Bolin Geng, Andrew A. Godfrey, Stewart L. Fisher	2012	65
13	Novel compounds targeting bacterial DNA topoisomerase/DNA gyrase Current Opinion in Pharmacology ·David E. Ehmann, Sushmita D. Lahiri	2014	63
14	Chain Termination Steps in Nonribosomal Peptide Synthetase Assembly Lines: Directed Acyl-S-Enzyme Breakdown in Antibiotic and Siderophore Biosynthesis ChemBioChem ·Thomas A. Keating, David E. Ehmann, Rahul M. Kohli, C. Gary Marshall, John W. Trauger, Christopher T. Walsh	2001	62
15	Characterization of Mercury(II) Complexes of Bis[(2-pyridyl)methyl]amine by X-ray Crystallography and NMR Spectroscopy Inorganic Chemistry ·Deborah C. Bebout, Anne E. DeLanoy, David E. Ehmann, Margaret E. Kastner, Damon A. Parrish, Ray J. Butcher	1998	54
16	Preparation of Mercury(II) Complexes of Tris[(2-pyridyl)methyl]amine and Characterization by X-ray Crystallography and NMR Spectroscopy Inorganic Chemistry ·Deborah C. Bebout, David E. Ehmann, Jonathan C. Trinidad, Kathleen K. Crahan, Margaret E. Kastner, Damon A. Parrish	1997	47
17	Inhibition of Neisseria gonorrhoeae Type II Topoisomerases by the Novel Spiropyrimidinetrione AZD0914 Journal of Biological Chemistry ·Günther Kern, Tiffany Palmer, David E. Ehmann, Adam B. Shapiro, Beth Andrews, Gregory S. Basarab, P. Doig, Jun Fan, Ning Gao, Scott D. Mills, John P. Mueller, Shubha Sriram, Jason Thresher, Grant K. Walkup	2015	39
18	Selectivity of the Yersiniabactin Synthetase Adenylation Domain in the Two-Step Process of Amino Acid Activation and Transfer to a Holo-Carrier Protein Domain Biochemistry ·Thomas A. Keating, Zucai Suo, David E. Ehmann, Christopher T. Walsh	2000	39
19	NBTI 5463 Is a Novel Bacterial Type II Topoisomerase Inhibitor with Activity against Gram-Negative Bacteria and In Vivo Efficacy Antimicrobial Agents and Chemotherapy ·Thomas J. Dougherty, Asha S. Nayar, Joseph Newman, Sussie Hopkins, Gregory G. Stone, Michele Johnstone, Adam B. Shapiro, M Cronin, Folkert Reck, David E. Ehmann	2014	38
20	Myostatin and activin blockade by engineered follistatin results in hypertrophy and improves dystrophic pathology in mdx mouse more than myostatin blockade alone Skeletal Muscle ·Andrea Iskenderian, Nan Liu, Qingwei Deng, Yan Huang, Chuan Shen, Kathleen Palmieri, Robert Crooker, Dianna Lundberg, Niksa Kastrapeli, Brian Pescatore, Alla Romashko, John Dumas, Robert D. Comeau, Angela W. Norton, Jing Pan, Haojing Rong, Katayoun Derakhchan, David E. Ehmann	2018	36

About David E. Ehmann

David E. Ehmann is a scholar working on Molecular Medicine, Pharmacology, Microbiology, Molecular Biology and Toxicology, having authored 29 papers that have together received 2.2k indexed citations. Recurring topics across this work include Antibiotic Resistance in Bacteria (12 papers), Cancer therapeutics and mechanisms (10 papers), Antibiotics Pharmacokinetics and Efficacy (9 papers), Microbial Natural Products and Biosynthesis (7 papers), Biochemical and Structural Characterization (4 papers), Muscle Physiology and Disorders (3 papers), Advanced NMR Techniques and Applications (2 papers) and Chemical Synthesis and Analysis (2 papers). The work is most often cited by research in Molecular Medicine (1.1k citations), Applied Microbiology and Biotechnology (199 citations), Pharmacology (1.0k citations), Endocrinology (158 citations) and Toxicology (61 citations). David E. Ehmann has collaborated with scholars based in United States, United Kingdom and Canada. Frequent co-authors include Christopher T. Walsh, Stewart L. Fisher, Rong-Fang Gu, Haris Jahić, Grant K. Walkup, Philip L. Ross, Jun Hu, Sushmita D. Lahiri, Günther Kern and Jason Thresher. Their work appears in journals such as Antimicrobial Agents and Chemotherapy, Journal of Biological Chemistry, ChemBioChem, Journal of Medicinal Chemistry and Biochemistry.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact